Cargando…
Treatment of age-related macular degeneration: focus on ranibizumab
Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A, significantly slows down loss of vision and causes significant visual improvement in many patients with choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). These benefit...
Autores principales: | Spitzer, Martin S, Ziemssen, Focke, Bartz-Schmidt, Karl U, Gelisken, Faik, Szurman, Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698673/ https://www.ncbi.nlm.nih.gov/pubmed/19668384 |
Ejemplares similares
-
Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
por: Dimopoulos, Spyridon, et al.
Publicado: (2015) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
por: Wachtlin, Joachim, et al.
Publicado: (2020) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008) -
Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)